EUVIMEDEUVIMED entdecken
Open Access

Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?

Ömer Uludağ iD, Suzan Çinar iD, Thomas McDonnell iD, Erhan Çene iD, Yasemin Yalçinkaya iD, Ahmet Gül iD, Murat Inanç iD, Bahar Artim Esen iD

Turkish Journal of Medical Sciences · 26.10.2023 · 53 (5) · 1067-1074

DOI: 10.55730/1300-0144.5671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 26.10.2023. Verfasst von Ömer Uludağ und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Thrombosis, Antibodies, Antiphospholipid. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aim: In this cross-sectional study, it was aimed to test the predictive value of noncriteria antiphospholipid antibodies (aPL) in addition to the global antiphospholipid syndrome score (GAPSS) in predicting vascular thrombosis (VT) in a cohort of patients with APS and aPL (+) systemic lupus erythematosus (SLE). Material and methods: This study included 50 patients with primary APS, 68 with SLE/APS, and 52 with aPL (+) SLE who were classified according to VT as VT ± pregnancy morbidity (PM), PM only or aPL (+) SLE. Antiphospholipid serology consisting of lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin G (IgG)/IgM/IgA, antibeta2 glycoprotein I (aß2GPI) IgG/IgM/IgA, antiphosphatidylserine/prothrombin (aPS/PT) IgG/IgM and antidomain-I (aDI) IgG was determined for each patient. The GAPSS and adjusted GAPSS (aGAPSS) were calculated for each patient, as previously defined. Logistic regression analysis was carried out with thrombosis as the dependent variable and high GAPSS, aCL IgA, aß2GPI IgA, and aDI IgG as independent variables.

Results

The mean GAPSS and aGAPSS of the study population were 11.6 ± 4.4 and 9.6 ± 3.8. Both the VT ± PM APS (n = 105) and PM only APS (n = 13) groups had significantly higher GAPSS and aGAPSS values compared to the aPL (+) SLE (n = 52) group. The patients with recurrent thrombosis had higher aGAPSS but not GAPSS than those with a single thrombotic event. The computed area under the receiver operating characteristic curve demonstrated that a GAPSS ?13 and aGAPSS ?10 had the best predictive values for thrombosis. Logistic regression analysis including a GAPSS ?13, aCL IgA, aß2GPI IgA, and aDI IgG showed that none of the factors other than a GAPSS ?13 could predict thrombosis.

Conclusion

Both the GAPSS and aGAPSS successfully predict the thrombotic risk in aPL (+) patients and aCL IgA, aß2GPI IgA, and aDI IgG do not contribute to high a GAPSS or aGAPSS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeThrombosisAntibodies, AntiphospholipidHumansFemaleAdultMaleCross-Sectional StudiesRisk AssessmentMiddle AgedLupus Erythematosus, SystemicPregnancyAntibodies, Anticardiolipin

Stichwörter der Autor:innen

Antiphospholipid syndromeglobal antiphospholipid syndrome scorenon-criteria antiphospholipid antibodiesthrombotic risk

Substanzen

Antibodies, AntiphospholipidAntibodies, Anticardiolipin

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye.
  • Department of Immunology, Aziz Sancar Institute of Experimental Medicine, İstanbul University, İstanbul, Turkiye.
  • Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom.
  • Department of Statistics, Faculty of Arts and Science, Yıldız Technical University, İstanbul, Turkiye.

ORCID-Profile: Ömer Uludağ, Suzan Çinar, Thomas McDonnell, Erhan Çene, Yasemin Yalçinkaya, Ahmet Gül, Murat Inanç, Bahar Artim Esen

Zitieren

APA

Uludağ, Ö., Çinar, S., McDonnell, T., Çene, E., Yalçinkaya, Y., Gül, A., Inanç, M., & Artim Esen, B. (2023). Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. Turkish Journal of Medical Sciences, 53(5), 1067-1074. https://doi.org/10.55730/1300-0144.5671

Vancouver

Uludağ Ö, Çinar S, McDonnell T, Çene E, Yalçinkaya Y, Gül A, et al. Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?. Turkish Journal of Medical Sciences. 2023;53(5):1067-1074. doi:10.55730/1300-0144.5671

BibTeX
@article{Uluda2023,
  author = {Uludağ, Ömer and Çinar, Suzan and McDonnell, Thomas and Çene, Erhan and Yalçinkaya, Yasemin and Gül, Ahmet and Inanç, Murat and Artim Esen, Bahar},
  title = {Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?},
  journal = {Turkish Journal of Medical Sciences},
  year = {2023},
  volume = {53},
  number = {5},
  pages = {1067--1074},
  doi = {10.55730/1300-0144.5671}
}
Kostenlos starten →